Who is now eligible for Emgality on the PBS?

From 1 June 2026, people with 8 or more migraine days per month are eligible — a significant expansion from the previous restriction of 15 or more headache days monthly (chronic migraine). You still need to have tried and failed adequate trials of established preventive medicines, and the PBS prescription must come from a neurologist or pain specialist. Your GP is the starting point: they can assess your treatment history against the criteria and make the referral.

How do I access Emgality on the PBS for episodic migraine?

You need a prescription from a neurologist or pain specialist — a GP referral is the starting point. The 50% response criterion at 6 months applies: if your migraine frequency or severity has not improved by at least half from your documented baseline, PBS-subsidised access does not continue. Your GP can document your current migraine frequency now, which forms the baseline for that 6-month assessment.

Can I switch from Botox to Emgality on the PBS?

You cannot access both onabotulinumtoxinA (Botox) and galcanezumab (Emgality) on the PBS at the same time. If you are currently receiving Botox on the PBS for migraine prevention, discuss whether switching to Emgality is clinically appropriate with your specialist before making any changes.

How is Emgality different from older migraine preventives like propranolol or amitriptyline?

Galcanezumab (Emgality) is a CGRP monoclonal antibody — it targets calcitonin gene-related peptide, a neuropeptide that plays a central role in migraine pathophysiology. Older preventives (beta-blockers, tricyclics, anticonvulsants) were repurposed from other conditions and have broader side-effect profiles. CGRP inhibitors were designed specifically for migraine and tend to be better tolerated, with monthly or quarterly self-injection.

Emgality now PBS-listed for episodic migraine from June 2026

What just happened

From 1 June 2026, galcanezumab (Emgality) is PBS-listed for high-frequency episodic migraine — specifically, for people with 8 or more migraine days per month. This is a significant expansion of access. Previously, PBS coverage required chronic migraine — defined as 15 or more headache days per month — a threshold that excluded many Australians with severe, debilitating episodic migraine.

The cost difference is substantial. Without subsidy, galcanezumab runs approximately $530 per monthly injection. Under the new PBS listing, eligible patients pay a maximum of $25 per script, or $7.70 with a concession card. Around 135,000 Australians per year are expected to benefit from this expanded listing.

Galcanezumab is a CGRP (calcitonin gene-related peptide) monoclonal antibody. The Australian Prescriber review describes how CGRP is a neuropeptide heavily implicated in migraine pathophysiology — it is released during attacks, dilates blood vessels, and lowers the threshold for pain signalling. Galcanezumab binds to CGRP and prevents it from activating its receptor, reducing both attack frequency and severity. Unlike older preventives — beta-blockers, tricyclic antidepressants, anticonvulsants — which were repurposed from other conditions, CGRP inhibitors were designed specifically for migraine.

For the woman who has been cancelling plans because of a migraine that arrives 10 days into every month, who has tried two or three preventive medications with partial or no benefit, who has looked at a CGRP inhibitor and mentally closed the browser at $500 per month: this is a real change in what is available to her.

The both-and

This expansion genuinely changes lives for people with severe episodic migraine. The criteria still carry barriers. Both are real.

What the trials show

The clinical evidence for galcanezumab is solid. In randomised controlled trials, approximately one-third of people with episodic migraine experienced a 50% or greater reduction in monthly migraine days, and a meaningful proportion achieved even greater reductions. The phase 3 EVOLVE trials that formed the basis of the registration and PBS evidence showed galcanezumab reduced mean monthly migraine days by approximately 4 to 5 days compared to placebo in people with high-frequency episodic migraine at 6 months. That is clinically meaningful across multiple domains — work capacity, social planning, and the basic ability to make commitments without qualifying them. For people who have been cycling through propranolol, amitriptyline, topiramate, and sodium valproate with limited benefit — the standard preventive options available on the PBS — the arrival of a new mechanistic class at an affordable price point is genuinely significant.

The 8 migraine days per month threshold is a meaningful broadening of the previous criterion. Eight migraine days per month is two or more per week — a pattern that substantially disrupts work capacity, relationships, and quality of life. The previous 15-headache-day threshold described a level of disability that required significant medical documentation and often specialist involvement before PBS access was possible. Many people with severe episodic migraine have been paying out of pocket, going without, or using older medicines that were poorly tolerated.

The criteria still have structure

To access galcanezumab on the PBS, you need to have trialled and failed adequate courses of established preventive medicines. The exact prior-treatment requirement is documented in the PBS restriction — your GP can review your treatment history against it before referral.

The PBS prescription itself requires a neurologist or pain specialist, not a GP. This is the structural friction point for most patients. Neurology and pain specialist waitlists in Australia — particularly outside major metropolitan centres — can run to many months for non-urgent referrals, and patients in regional and rural settings face a longer pathway. The GP’s role is not passive here: a GP who knows this PBS expansion exists can refer now, document the baseline migraine frequency and severity that the response criterion will be measured against, and orient the patient toward the pathway before she has exhausted other options or given up. That orientation is a clinical service.

The 6-month response criterion

PBS access is conditional on demonstrating at least a 50% reduction in migraine frequency from your documented baseline at the six-month continuation point. If that threshold is not met, PBS-subsidised access does not continue. This is consistent with how most preventive migraine therapies are managed on the PBS, and the majority of people who respond to CGRP inhibitors do so within the first 3 months. But it is a clinical effectiveness gate: it creates an access cliff edge for partial responders, and it adds a review burden that requires proactive coordination between the patient, the prescribing specialist, and the GP.

The Botox restriction

Galcanezumab and onabotulinumtoxinA (Botox) cannot be accessed on the PBS simultaneously. Botox is PBS-listed for chronic migraine (15+ days per month) and has been the dominant PBS-funded preventive for that population for several years. For patients already accessing Botox on the PBS who are interested in switching to a CGRP inhibitor, the decision to switch requires a specialist discussion about clinical fit, response history, and access timing. It is not a reason to avoid galcanezumab — it is a reason to have the conversation while informed.

The perimenopause dimension

The perimenopausal and menopausal dimension is worth naming explicitly. Migraine affects three times as many women as men over the adult lifespan, with a peak prevalence in the 35–55 age bracket. The hormonal fluctuations of perimenopause — particularly falling and fluctuating oestrogen levels — are among the best-documented triggers for migraine worsening. Women who have had relatively manageable migraine for years sometimes find their pattern changes substantially in the perimenopause: more frequent attacks, longer duration, greater resistance to acute treatments — symptoms too often minimised as hormonal and left undertreated. A CGRP inhibitor at $25/month may now be the most clinically and practically accessible preventive option for this group, where older agents like valproate are contraindicated in women of childbearing potential.

2 cents

If you have 8 or more migraine days per month and have tried and not responded adequately to preventive medicines: the June 1 PBS expansion is directly relevant to a conversation worth having with your GP this month. Specifically: does your clinical history satisfy the PBS restriction criteria, and is a referral for galcanezumab now the appropriate next step in your preventive strategy?

The practical starting point: ask your GP to document your current migraine frequency and severity clearly in your notes. That baseline is what the 6-month response criterion is measured against, and establishing it now means you are not starting the PBS clock from zero when the specialist script is finally written.

If you have been paying out of pocket for Emgality or a similar CGRP inhibitor (Ajovy/fremanezumab is also PBS-listed for chronic migraine): check with your prescriber whether the new episodic migraine restriction changes your subsidy eligibility or PBS coverage terms.

If your migraine has changed in character — more frequent, more severe, harder to treat with your usual abortive medicines — during the perimenopause years: this is a pattern worth raising explicitly with your GP, who can assess whether migraine review, preventive therapy, or hormonal management is the most appropriate pathway.

This is general information about a PBS listing change. Whether you are eligible for subsidised galcanezumab depends on your individual clinical history and the current PBS restriction criteria. Your GP or a neurologist can assess this.

Verdict

Verdict: yes — worth knowing about.

The June 1 PBS expansion of galcanezumab (Emgality) to high-frequency episodic migraine (8+ migraine days/month) is a meaningful access change for a large number of Australians who have been excluded from CGRP inhibitor therapy by cost or the previous chronic-migraine threshold. The specialist-prescription requirement and the 6-month response criterion create real barriers — so the immediate, practical move is the GP visit: know the listing exists, document the baseline, make the referral. If you or someone you know has severe episodic migraine and has been managing with inadequate older preventives or paying full cost for a CGRP inhibitor, this is the conversation to have now.